We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results: 1-10 of 523

Symed Labs wins process patent protection at Delhi High Court
  • RNA, Intellectual Property Attorneys
  • India
  • July 8 2015

Symed Labs invented a new process for preparation of Linezolid as compared to the earlier existing processes which were tedious and cumbersome. Symed

Compulsory license for AstraZeneca’s diabetes management drug Saxagliptin?
  • Khaitan & Co
  • India
  • July 7 2015

In a recent development, a compulsory license (CL) application has been filed for the patent covering AstraZeneca's diabetes management drug

Phonetic similarity is the key - court holds GENTAC similar to ZANTAC and ZINETAC
  • RNA, Intellectual Property Attorneys
  • India
  • July 2 2015

Glaxo Group Ltd being aggrieved with Systochem Lab’s use of the brand GENTAC for gastro medicines initiated an action against them before the Delhi

Helping the generic market: the Bolar exemption
  • LexOrbis Consulting Pvt Ltd
  • India
  • June 17 2015

A lot of water has flowed under the bridge since the United States enacted the Drug Price Competition and Patent Term Restoration Act 1984, commonly

The battle over sitagliptin between Merck and Glenmark reaches the Supreme Court
  • Lakshmikumaran & Sridharan
  • India
  • May 27 2015

Nearly two years after Merck initiated an infringement action against Glenmark before the Delhi High Court over its Patented diabetics drug

Competition commission conditionally approves Sun-Ranbaxy deal
  • Vaish Associates Advocates
  • India
  • May 14 2015

In a December 5 2014 order the Competition Commission conditionally approved the proposed merger between Sun Pharma and Ranbaxy, subject to the

Generics vs. patented drugs
  • KASS International
  • India, Malaysia
  • April 27 2015

India's incredible advancement in various fields of technology (including launching its own first ever Mars mission!) has attracted other nations to

Patent controller revokes Boehringer’s patent based on Cipla’s post-grant opposition
  • Lakshmikumaran & Sridharan
  • India
  • April 15 2015

In its latest rejection of a pharmaceutical patent the Patent Office rejected Patent 254813, granted to Boehringer Ingelheim Pharma Gmbh, in a

Pharmaceuticals & healthcare newsletter - April 2015
  • Baker & McKenzie
  • India, Malaysia, Singapore
  • April 6 2015

The Singapore Ministry of Health (the "MOH") recently issued a set of National Telemedicine Guidelines (the "NTG"). Telemedicine is the systematic

Cipla-Novartis is revocation a reasonable solution?
  • LexOrbis Consulting Pvt Ltd
  • India
  • March 20 2015

On October 21 2014 Cipla, one of India's largest generic drug manufacturers, sought revocation of five of Novartis's patents under Sections 66 and 92